The US Food and Drug Administration (FDA) on Monday finalized guidance to pharmaceutical and biotech sponsors looking for more advice on when non-inferiority studies demonstrating effectiveness of an ...
All new antibiotics approved by the US Food and Drug Administration (FDA) used surrogate outcome measures, and about half had pivotal trials with a non-inferiority design, according to recent research ...
Signati™ Medical, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational Device Exemption (IDE) application for a randomized pivotal clinical ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
Prosigna identified a large high-clinical-risk subgroup with minimal chemotherapy benefit, estimated to avert at most two recurrences per 100 patients treated. Enrollment broadened prior assay use by ...
FAST III was initiated five years ago to evaluate whether revascularization guided by angiography–based FFR using CAAS vFFR (vessel Fractional Flow Reserve) delivers therapeutic outcomes comparable to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results